Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome

IRVING, Texas, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ( “Reata” or the “Company”) today announced the initiation of patient screening in a Phase 2/3 trial to evaluate bardoxolone methyl (“bard”) in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials